Leadership In Controlled Gene Expression


Newsletter

Stay updated with our activities by reading our newsletter.


Highlighted Publications


>> Read More

 

 

 

 

 

 

BizCom Japan, Inc. and TET Systems GmbH & Co. KG sign Marketing Agreement for the Tet Technology in Japan

Tokyo, Japan and Heidelberg, Germany; 13 May 2013 – BizCom Japan, Inc., a privately-held, a Japan-based trading and consulting company, and TET Systems GmbH & Co. KG, a privately-held, German-based biotech company, announced today that they have entered into a marketing agreement.

BizCom Japan, Inc. has been engaged in sales and marketing of research reagents, services and equipment to the life science research market in Japan and consulting for innovative biotech companies in Japan as well as other countries, and has extensive experience in establishing various types of alliances with Japanese companies and public institutions. BizCom Japan, Inc. will use this experience and its sales and marketing expertise to exclusively market the Tet Technology for TET Systems GmbH & Co. KG in Japan.

About BizCom Japan, Inc.

BizCom Japan, Inc. is a trading and consulting company based in Tokyo, Japan. From its foundation in 1996, it has been collaborate with various innovative companies in biotechnology, pharmaceutical, diagnostic, cosmetic and medical device industries. In addition to providing research reagents, services and equipment to the life science research market, BizCom Japan actively intermediates in- and out-licensing of various cutting-edge technologies for its collaborators. Through strategic alliances with its collaborators, the Company aims to extend its reach around the world. More information is available at www.bizcomjapan.com.

About TET Systems GmbH & Co. KG

TET Systems GmbH & Co. KG is a privately held company located in Heidelberg, Germany. TET Systems GmbH & Co. KG was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the TET Technology, the most widely used method to control gene expression in higher organisms.  TET Systems GmbH & Co. KG owns a broad patent portfolio covering the technology organised in six patent families comprising 45 patents and 9 patent applications. To date, more than 170 organisations have licensed the TET Technology including academic institutions and research foundations. The largest group of partners are biotech and pharmaceutical companies, with 17 of the top 20 BIG Pharma (2006) being TET Technology licensees.

 

All trademarks are the property of their respective owners.


TET Systems GmbH & Co. KG                                                          

Dr. Ernst Böhnlein                                                       

Chief Executive Officer                                      

Phone: +49 6221 588 0400                   

boehnlein@tet-systems.com

 

You can download the press release as pdf file in English and Japanese.


Recordings of Tet webinar series are now available

Together with Clontech/Takara-Bio Europe, TET Systems hosted a series of four webinars in December 2012.

Webinars:

     Prof. Dr. Dr. h.c. Hermann Bujard, University of Heidelberg, Germany 

     Dr. Kai Schönig, Central Institute of Mental Health, Mannheim, Germany 

     Dr. Manfred Gossen, BCRT, Berlin, Germany 

     Dr. Michael Elser, Product Manager, Clontech/Takara Bio Europe, France

      Dr. Luke Alphey, Chief Scientist, Oxitec Ltd., UK  

      Prem K. Premsrirut, PhD, CEO of Mirimus, Inc.

 

You can access the webinar recordings and Q&A transcripts by clicking on the title of the respective webinar.

 

To top


TET Systems and Takara Bio Europe together launch a series of Webinars on the Tet Technology

Paris France, November 20, 2012—Takara Bio Europe (St.-Germain-en-Laye) and TET Systems (Heidelberg) announced today that they would be hosting a series of four webinars on the Tet Technology in the first half of December 2012. This webinar series aims to provide additional insights into the most successful technology for controlling gene expression in eukaryotes and how to best use it.

Controlled gene expression is a method used to study the function of eukaryotic genes. The Tet technology is the most widely cited inducible mammalian expression system used today for this purpose. It was invented 20 years ago by Prof. Bujard and Dr. Gossen, at the Center for Molecular Biology (ZMBH) at the University of Heidelberg. Continuous improvements of the technology, by the inventors as well as by scientists using the technology, have led to the development of the 3rd generation of Tet technology which combines extremely tight control of gene expression with the ability to induce expression several thousand fold.

The Tet technology consists of a chimeric transactivator protein and a Tet-specific promoter which the transactivator binds to in response to the presence (Tet-On®) or absence (Tet-Off®) of the tetracycline analogue doxycycline. The Tet systems turn the expression of a gene of interest on or off at will, in a dose-dependent and reversible manner. In particular, the fully reversible nature of the Tet technology has enabled breakthrough insights into mechanisms of learning in animals by the Kandel group, and in the field of oncology. Other recent applications include the expression of inhibitory RNAs, and inducible pluripotent stem cells.

Webinars

Tuesday December 4, 4 pm CET

Studying Gene Function by Controlling Expression in vivo

Prof. Dr. Dr. h.c. Hermann Bujard, University of Heidelberg, Germany

Wednesday December 5, 4 pm CET

Controlling Gene Expression in transgenic mice

Dr. Kai Schönig, Central Institute of Mental Health, Mannheim, Germany

Tuesday December 11, 4 pm CET

Tet System: selected applications

Dr. Manfred Gossen, BCRT, Berlin, Germany

Wednesday December 12, 4 pm CET

Getting started with Tet-induced gene expression - Choosing the right system for your application

Dr. Michael Elser, Product Manager, Clontech/Takara Bio Europe, France

See registration page for abstracts of the webinars: www.clontech.com/tetwebinar

- Ends -

 

 About the speakers

Hermann Bujard has held positions in academia and industry. In 1970 he was offered the chair of Molecular Genetics at Heidelberg University, and from 1980 to 1985 he was Head of Biological Research and Deputy Director at F. Hoffmann-La Roche in Basel, Switzerland. He returned to Heidelberg to the ZMBH (Center for Molecular Biology) in 1983 after being offered the chair of molecular biology. His research has long been driven by his interest in mechanisms of gene regulation at the transcriptional level as documented by a long list of publications among these (together with Manfred Gossen) on the invention of the Tet technology in 1992. In 1995 Prof. Bujard received the “Beckurts“ award and in 1996 the “Prix Yvette Mayent”. Hermann Bujard founded TET Systems in 2003 together with Manfred Gossen and the late Wolfgang Hillen.

Manfred Gossen is co-inventor of the Tet technology. He started his studies in Bonn, Germany before moving to Heidelberg, where he joined Prof. Bujard’s research group at the Center for Molecular Biology, University of Heidelberg. During research on his PhD thesis into the use of prokaryotic transcription elements for control of gene expression in higher eukaryotes, he developed the original Tet system (Tet-Off). Together with Hermann Bujard he also contributed over the years to improvements of the available reagents which are sold by Clontech and Takara Bio Europe. Dr. Gossen currently heads the research group on Genetic Engineering at the “BCRT” in Berlin.

Kai Schönig is a former member of Prof. Bujard’s laboratory at the Center for Molecular Biology, University of Heidelberg, where he was generating several Tet transgenic mouse lines during his PhD thesis. He now is at the Central Institute of Mental Health in Mannheim, Germany, where he uses the Tet technology to develop mouse and rat models to study neurological disorders.

Michael Elser has many years’ of experience in advising and troubleshooting experimental setups for Clontech’s Tet-inducible products at Takara Bio Europe. He has a PhD from the University of Zurich, Switzerland, and did post-doctoral research at the Institut Pasteur in Paris, France, where he worked on signalling pathways in allergy.


About TET Systems

TET Systems GmbH & Co. KG (TET Systems) is a privately held company located in Heidelberg, Germany. TET Systems was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the Tet Technology, the most widely used method to control gene expression in higher organisms. TET Systems owns a broad patent portfolio covering the technology organized in six patent families comprising 41 granted patents and 13 patent applications. To date, more than 220 organizations have licensed the Tet Technology including academic institutions and research foundations. The largest group of licensees are pharmaceutical and biotech companies, with 17 of the top 20 BIG Pharma (2010) being Tet Technology licensees. For more information see www.tetsystems.com.

 

About Takara Bio Europe, SAS

Takara Bio Europe, SAS and Clontech Laboratories, Inc., are members of the Takara Bio Group, which develops, manufactures, and distributes a wide range of life science research reagents under the Clontech and Takara brands. Key products include the Living Colors® fluorescent proteins; high-performance qPCR and PCR reagents including the Ex Taq™, LA Taq™, Titanium®, and Advantage® enzymes; RT enzymes and SMART™ library construction kits; the innovative In-Fusion® cloning system and Tet-On® and Tet-Off® inducible gene expression systems. Takara Bio Europe’s highly qualified specialists not only have in‐depth knowledge of the products, but also an excellent understanding of research customers’ specific needs and applications.                  

 

See www.takara‐bio.eu and www.clontech.com for more information.

 

 

Contact

TET Systems GmbH & Co. KG

Dr. Ernst Böhnlein

Managing Director

Phone: +49 (6221) 588 0400

boehnlein@tet-systems.com

 

Takara Bio Europe, SAS

Jean-Jacques Farhi

President

+33 (0)1 39046882

jean-jacques.farhi@takara-bio.eu

 

You can also download the press release as pdf file.

To top


Pachyonychia Congenita (PC) Project and TET Systems sign license agreement

Heidelberg and Salt Lake City, May 29, 2012. PC Project, a US public 5031(c)(3) charity headquartered in Salt Lake City, UT and TET Systems, a privately-held, German biotech company based in Heidelberg announced today that they have signed a license agreement. Under the terms of this agreement, PC Project and its collaborators can use the Tet Technology for the discovery and development of methods to diagnose, treat or cure Pachyonychia Congenita, a very rare genetic disorder.

As Mary Schwartz, Director of PC Project, explains “PC patients are in urgent need of an effective treatment for this rare skin disease. Both adults and children experience extreme pain from blisters and callus on the soles of the feet, cysts, thickened nails and other disabling problems caused by a mutation in a single keratin gene. We are excited that scientists in our PC consortium, who are working with us to develop treatments for PC, will be able to use the important Tet Technology in their laboratory work. We are confident this agreement provides a valuable asset in PC research efforts to find solutions that can be used in the clinic to improve the lives of PC patients as immediately as possible.

“We are happy that we have signed this agreement with PC Project and hope that the use of our proprietary technology will help PC Project and its affiliated researchers to improve the situation of patients suffering from this disease,” said Dr. Ernst Böhnlein, Managing Director of TET Systems. ”We were unaware of this very rare genetic disease before and decided to support PC Projects` research not only by providing access to the Tet Technology but to also directly support PC Projects` great cause to generate awareness for PC and to find treatments.”

 

About TET Systems

TET Systems is a privately held company located in Heidelberg, Germany. TET Systems was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the Tet Technology, the most widely used method to control gene expression in higher organisms. TET Systems owns a broad patent portfolio covering the technology organized in six patent families comprising 41 granted patents and 13 patent applications. To date, more than 200 organizations have licensed the Tet Technology including academic institutions and research foundations. The largest group of licensees are pharmaceutical and biotech companies, with 17 of the top 20 BIG Pharma being Tet Technology licensees.

 

Contact:

TET Systems GmbH & Co. KG
Dr. Ernst Böhnlein
Managing Director
Phone: +49 (6221) 588 0400
boehnlein@tet-systems.com

Pachyonychia Congenita Project

Mary E. Schwartz, Director
2386 East Heritage Way, Suite B
Salt Lake City, UT 84109, USA
Phone: +1 (801) 401-6300
info@pachyonychia.org

 

You can download the PR as pdf-file here.

To top


Clontech Laboratories, Inc. Releases the Tet-Express™ Inducible Expression System

February 17th, 2011

Mountain View, CA—February 17th, 2011—Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the release of the Tet-Express Inducible Expression System, which provides the quickest and simplest Tet-inducible expression technology yet. At the heart of this new system is a cell membrane-permeable version of Clontech’s Tet-Off® Advanced transcriptional activator protein (the Tet-Express transactivator) that can enter cells directly, i.e., without transfection. The Tet-Express system eliminates the requirement for a double-stable cell line expressing both the gene of interest and the tetracycline transactivator. Instead, only the gene of interest is cloned into the cells; then when gene expression is required, simply add the self-transducing Tet-Express protein directly to the cells in order to turn on the gene of interest. Since the Tet-Express protein binds and activates expression in the absence of tetracyclines, doxycycline is not required for gene activation, further simplifying the system. Clontech has filed for patent protection for the Tet-Express system.

Carol Lou, General Manager of Clontech Laboratories, Inc., comments: “Clontech has a long history of leadership in developing technologies for gene delivery and expression. We are pleased to continue and extend this history by adding the Tet-Express Inducible Expression System to our portfolio of Tet System Products, which are the gold standard for regulated gene expression.”

For maximal expression and minimal background, the Tet-Express Inducible Expression System contains Clontech’s latest and tightest Tet System promoter, PTRE3G, which is found in Clontech’s Tet-On® 3G Expression Systems (developed and marketed under a license from TET Systems GmbH and Co. KG). The Tet-Express System makes tetracycline-controlled transcription a rapid process for all cell types, and is particularly advantageous for cell types that are not amenable to sequential rounds of clonal selection. In addition, the Tet-Express System provides a novel way to screen clones for inducible expression of the gene of interest before moving on to make stable lines, by allowing the researcher to test induction in the clones simply by adding the Tet-Express transactivator to the culture medium.

 

About Clontech Laboratories, Inc.
Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Clontech and Takara brands. Key products include high-performance qPCR and PCR reagents (including the Ex Taq™, LA Taq™, Titanium®, and Advantage® enzymes); RT enzymes and SMART™ library construction kits; the innovative In-Fusion® cloning system; Tet-based inducible gene expression systems; and a range of Macherey-Nagel nucleic acid purification tools. These and other products support applications including gene discovery, regulation, and function; protein expression and purification; RNAi and stem cell studies; and plant and food research. For more information, visit www.clontech.com.

 

About Takara Bio Inc.
Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin® reagent, which is used as a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at www.takara-bio.com.

 

About TET Systems.
TET Systems is a privately held company located in Heidelberg, Germany. TET Systems was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the Tet Technology, the most widely used method to control gene expression in higher organisms. TET Systems owns a broad patent portfolio covering the technology organized in six patent families comprising 36 granted patents and 14 patent applications. TET Systems markets licenses to the Tet Technology. To date, more than 160 organizations have licensed the Tet Technology including academic institutions and research foundations. The largest group of licensees are pharmaceutical and biotech companies, with 17 of the top 20 BIG Pharma (2006) being Tet Technology licensees.


You can download the PR as pfd-file.


Contact Information

TET Systems GmbH & Co. KG
Dr. Ernst Böhnlein
Managing Director
Phone: +49 (6221) 588 0400


Clontech Laboratories, Inc.
Andrew Farmer, Ph.D.
Director, Business Development
Clontech Laboratories, Inc.
1290 Terra Bella Avenue
Mountain View, CA 94043
Tel: 650.919.7347
Fax: 650.493.5569
Email: andrew_farmer@clontech.com



To top


TET Systems’ licensee Oxitec Ltd. reports on successful field trial to reduce wild population of mosquito transmitting Dengue fever

Oxitec and MRCU joint press release (Nov. 4, 2010)

 

Dengue fever, a viral disease transmitted by the mosquito Aedes aegypti is a debilitating disease affecting 100 Mio people globally.   Symptoms of Dengue fever range from mild flu-like symptoms to hemorrhagic fever which, unless treated promptly, may lead to shock and death. Currently there is no specific medication nor a vaccine for Dengue fever, the only way to control the disease is to control the transmitting mosquito.

TET Systems’ UK-based licensee Oxitec has developed a strain of Aedes aegypti  that is homozygous for a lethal gene and is conditionally sterile. Sterility is controlled by the Tet-Off transactivator and will only develop in a Tc-free environment e.g. after release of the insects into the wild where genetically modified males will mate with wildtype females but will not produce any progeny. If large numbers of sterile males are released repeatedly, they will outnumber their wildtype counterparts which will eventually lead to a decline of the whole population.

A few days ago, Dr. Luke Alphey, Oxitecs’ founder and CSO reported at the annual meeting of The American Society of Tropical Medicine and Hygiene results of their first open field trial. The trial took place on Grand Cayman where engineered males were released for several months. Dr. Alphey reported that all the trial objectives were successfully met, most importantly the local Aedes population declined by 80% three months after the start of release of engineered mosquitoes.

This first application of Oxitec’s proprietary RIDL technology which comprises the Tet system in an open field trial gives hope that this approach can be applied in other countries to control Dengue fever and eventually may also provide a means to combat other mosquito-borne diseases.

To top


Clontech Laboratories, Inc. & TET Systems announce the broadening of their license agreement and the upcoming launch of the new Tet-On® 3G™ Inducible Expression System

Mountain View, CA and Heidelberg Germany—July 26, 2010—Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., and TET Systems (TET), a privately-held German biotech company based in Heidelberg, today announced that they have signed an amendment to their existing license agreement. Under the expanded license agreement, Clontech obtains rights to develop, manufacture and commercialize novel Tet Systems products as the Tet-On® 3G™ Inducible Expression System (www.clontech.com/teton3g).

The Tet-On 3G Inducible Expression System provides highly inducible, sensitive control of gene expression. It includes two novel components, the rights to which were acquired by TET in 2009: (i) an improved transcriptional activator developed by scientists at the Academic Medical Center at the University of Amsterdam (AMC) in the Netherlands, and (ii) a novel minimal Tet promoter developed at the University of Heidelberg in Germany.

The Tet-System currently marketed by Clontech is already the gold standard for regulated gene expression, as measured by more than 7,000 peer-reviewed scientific publications. The new Tet-On 3G Inducible Expression System offers researchers even greater control of gene regulation due to lower expression in the non-induced state, even in transient transfection settings. The system’s ten-fold increased sensitivity for the inducing agent (Doxycycline) will also expand the long-established benefits of dynamic transactivation, particularly for in vivo models.

Carol Lou, General Manager of Clontech Laboratories, Inc., comments: “Clontech has a long history of leadership in developing technologies for gene delivery and expression, and a long-standing partnership with TET Systems. We are pleased to continue and extend this history by adding the Tet-On 3G Inducible Expression System to our portfolio of Tet System Products, which also includes our inducible Lenti-X™ systems.”

Clontech is launching a broad suite of Tet-On 3G Inducible Expression Systems, including different promoters, fluorescent markers, and bicistronic systems, which will be available August 2nd, 2010.

 

About Clontech Laboratories, Inc.

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Clontech and Takara brands. Key products include high-performance qPCR and PCR reagents (including the Ex Taq™, LA Taq™, Titanium™, and Advantage® enzymes); RT enzymes and SMART™ library construction kits; the innovative In-Fusion™ cloning system; Tet-based inducible gene expression systems; and a range of Macherey-Nagel nucleic acid purification tools. These and other products support applications including gene discovery, regulation, and function; protein expression and purification; RNAi and stem cell studies; and plant and food research. For more information, visit www.clontech.com.

 

About Takara Bio Inc.

Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin® reagent, which is a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at www.takara-bio.com.

 

About TET Systems.

TET Systems is a privately held company located in Heidelberg, Germany. TET Systems was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the Tet Technology, the most widely used method to control gene expression in higher organisms. TET Systems owns a broad patent portfolio covering the technology organized in six patent families comprising 35 granted patents and 15 patent applications. TET Systems markets licenses to the Tet Technology. To date, more than 150 organizations have licensed the Tet Technology including academic institutions and research foundations. The largest group of licensees are pharmaceutical and biotech companies, with 17 of the top 20 BIG Pharma (2006) being Tet Technology licensees.

 

 

Contact Information

TET Systems GmbH & Co. KG

Dr. Ernst Böhnlein                                                      

Managing Director                                          

Phone: +49 (6221) 588 0400                 

boehnlein@tet-systems.com

 

Clontech Laboratories, Inc.

Andrew Farmer, Ph.D.

Director, Business Development

Clontech Laboratories, Inc.

1290 Terra Bella Avenue

Mountain View, CA 94043

Tel: 650.919.7347

Fax: 650.493.5569

andrew_farmer@clontech.com

 

You can download the PR here.

 

To top


TET Systems and SIRION BIOTECH GmbH sign a commercial license agreement

Press Release June 24, 2010

Heidelberg. TET Systems (TET) and SIRION BIOTECH GmbH, two privately-held, German biotech companies based in Heidelberg and Martinsried near Munich, respectively, announced today that they have signed a commercial license agreement. Under the terms of the agreement, SIRION BIOTECH offers customized services to its clients using the Tet Technology to generate cell lines and to generate and manufacture recombinant viral vector products.

“We are very pleased to sign this commercial license agreement with SIRION BIOTECH. The services offered by SIRION BIOTECH, in particular the recombinant adenoviral production services, have not been available through our existing Authorized Partner Network and SIRION BIOTECH’S addition nicely complements our existing network. Since there has been demand in the past for these services from our existing licensees and academic institutions we expect that this new agreement will be the basis for a successful business relationship with SIRION BIOTECH,” stated Dr. Ernst Boehnlein, CEO of TET Systems. “We will continue to add to our Partner Network to fill existing gaps, to accommodate our customers` demands and to make new technologies available to our licensees."

The license of the Tet Technology allows SIRION BIOTECH to switch on or turn off the induced gene products in genetically modified cells. The use of this technology expands the services of the company and helps to circumvent the disadvantages of traditional genetically modified cells with permanent gene expression. The Tet Technology leads to a broader application range of SIRION BIOTECH vectors. Hence Pharma and Biotech customers are able to achieve better results in screening and providing higher success rates in target validation

“With the licensing of the Tet Technology we are broadening our customer`s benefits fundamentally and therefore have added a substantial revenue driver to the services we already offer,” said Dr. Christian Thirion, CSO of SIRION BIOTECH

 

About TET Systems

TET Systems is a privately held company located in Heidelberg, Germany. TET Systems was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the Tet Technology, the most widely used method to control gene expression in higher organisms. TET Systems owns a broad patent portfolio covering the technology organized in six patent families comprising 35 granted patents and 15 patent applications. To date, more than 150 organizations have licensed the Tet Technology including academic institutions and research foundations. The largest group of licensees are pharmaceutical and biotech companies, with 17 of the top 20 BIG Pharma (2006) being Tet Technology licensees.

 

About SIRION BIOTECH

SIRION BIOTECH GmbH is a biotech company that produces genetically modified cells and is a technology provider in the area of viral vector systems. The company founded in 2006 is located in the Innovations- und Gründerzentrum Biotechnologie IZB in Martinsried near Munich. The expert in RNAi technology offers a wide range of more than 100 products and services. Using state-of-the art techniques and assay systems the company offers reliable lead-through service projects in target validation, screening and drug discovery.

With its strong expertise in cell line development SIRION BIOTECH serves as a partner for the development and optimization of cell lines for various applications like the production of vaccine or antibodies or the built up of cellular assay systems.

SIRION BIOTECH currently operates projects for most of the major pharmaceutical companies in Europe and USA and has ongoing collaborations with leading academic and governmental research institutes.

 

Contact:

TET Systems GmbH & Co. KG

Dr. Ernst Böhnlein

Chief Executive Officer

Phone: +49 6221 588 0400      

boehnlein@tet-systems.com

 

 SIRION BIOTECH GmbH

Holger Schmidt                 

PR Manager               

Phone: +49 8106-37 97 171

Fax: +49(0)8106-37 97 171

E-Mail: holgerachim.schmidt@web.de

www.sirion-biotech.de

 

You can download the PR here.

To top



TET Systems and IP Merchandisers Enter into a Merger Agreement

The business year 2009 has been a very successful year with a record number of newly signed Tet Technology licenses. Nevertheless, TET Systems decided to streamline its organization. Effective January 1, 2010, TET Systems, the owner of the Tet Technology IP Portfolio and its subsidiary and exclusive Licensee IP Merchandisers entered into a definitive merger agreement.

As a consequence, IP Merchandisers has been fully integrated into TET Systems. As legal successor, TET Systems will take over all practical licensing activities and will provide the quality support to all existing and new Tet Technology licensees.

 

About TET Systems

TET Systems Holding is a privately held company located in Heidelberg, Germany. TET Systems Holding was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the Tet Technology, the most widely used method to control gene expression in higher organisms.  TET Systems Holding owns a broad patent portfolio covering the technology organized in six patent families comprising 32 granted patents and 23 patent applications.  To date, more than 150 organizations have licensed the Tet Technology including academic institutions and research foundations.  The largest group of licensees are pharmaceutical and biotech companies, with 17 of the top 20 BIG Pharma (2006) being Tet Technology licensees.  

 

Contact:

TET Systems Holding GmbH & Co. KG

Dr. Ernst Böhnlein                    
Chief Executive Officer                
Phone: +49 6221 588 0400        
boehnlein@tet-systems.com

 

You can download the PR here.

To top



TET Systems and AMC/STW enter into an assignment agreement

Heidelberg and Amsterdam, December 2, 2009 - TET Systems Holding (TSH), a privately-held, German biotech company based in Heidelberg, the Academic Medical Center (AMC), and Technology Foundation STW announced today that they have entered into an assignment agreement.
Scientists at the AMC have previously developed a novel series of reverse transactivators with improved properties. Under the terms of the agreement, AMC and STW assign the rights to the eight patent applications covering these new Tet trans-activators to TSH for commercialization.
"We are very pleased to sign this agreement with AMC and STW. Since TET Systems was established in 2004, all relevant IP covering the Tet Technology was in one hand and could be offered to our licensees as a package. With the acquisition of these patent applications from AMC and STW, we broadened our IP portfolio and the rights to the core Tet Technology are again unified and can now be offered to our existing licensees and new interested parties, "stated Dr. Ernst Boehnlein, CEO of TET Systems. "TET Systems has been continuously growing its number of licensees and users of the Tet Technology over the past years. From now on, interested parties can again do ?one-stop shopping? for the relevant Tet Technology."
"We are excited to enter into this partnership with TET Systems Holding as it opens the way to broad use of our improved transactivators in the scientific community, but also in the biotech and pharma industry", added Dr. Joris Heus, of AMC?s Technology Transfer Office. "The existing scientific relationship between our researchers at AMC and the inventors of the Tet Technology formed the basis for the new IP generated at AMC and led to this agreement with TET Systems."

About TET Systems
TET Systems Holding is a privately held company located in Heidelberg, Germany. TET Systems Holding was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the Tet Technology, the most widely used method to control gene expression in higher organisms.  TET Systems Holding owns a broad patent portfolio covering the technology organized in six patent families comprising 31 granted patents and 14 patent applications.  TET Systems markets licenses to the Tet Technology through its subsidiary IP Merchandisers.  To date, more than 150 organizations have licensed the Tet Technology including academic institutions and research foundations.  The largest group of licensees are pharmaceutical and biotech companies, with 17 of the top 20 BIG Pharma (2006) being Tet Technology licensees.  

About AMC and STW
AMC: The Academic Medical Center (AMC) is one of the foremost research institutions in the Netherlands, as well as one of its largest hospitals. Over 7000 people work here to provide integrated patient care, fundamental and clinical scientific research, and teaching. The AMC complex houses the university hospital and the faculty of medicine of the University of Amsterdam, the Netherlands Institute for Neuroscience, the medical department of the Royal Tropical Institute and the Amsterdam Institute for Global Health and Development. A number of biotech companies (some of which are AMC spin-offs) are located on the premises. This concentration of expertise makes the centre a breeding ground for fruitful scientific collaboration.
The group of Prof. Ben Berkhout is among Europe?s leading groups in the field of HIV-related research, focusing on new therapies as well as basic research, which includes the viral evolution model that led to the development of the improved Tet transactivators.
STW: Technology Foundation STW aims to realize knowledge transfer between academic research and users in general and industry in particular by financing excellent scientific research in technology and unite researchers and potential users from the start.  The foundation was founded in 1981. Nowadays the STW office has 50 fte. About 500 projectleaders and 750 temporary scientists are working on STW research. There is an active cooperation with over 600 ventures.


Contact:
TET Systems Holding GmbH & Co. KG
Dr. Ernst Böhnlein                    
Chief Executive Officer                
Phone: +49 (6221) 588 0400        
boehnlein@tet-systems.com

Academic Medical Center (AMC)
Dr. Joris Heus
Technology Development Manager
Phone:    +31 (20) 5667911
j.heus@amc.uva.nl

Technology Foundation STW
Drs. Erwin Woord
Communication advisor
Phone: +31 (30) 6001 288
e.woord@stw.nl

You can download the news here.

To top



TET Systems and Novo Nordisk sign license agreement

TET Systems Holding GmbH & Co. KG ("TET Systems"), a worldwide leader in controlled gene expression, today announced that TET Systems and Novo Nordisk A/S have signed a license agreement allowing the Hagedorn Research Institute (HRI), a research institute within Novo Nordisk A/S, the use of the Tet Technology for its internal research activities.  

TET Systems was founded by Prof. Dr. H. Bujard and his colleagues.  Today, TET Systems` technology is the most widely used method to control gene expression in higher organisms.  85% of the world's leading pharmaceutical companies license the Tet Technology for their internal R&D activities. The broad usage of the Tet Technology is demonstrated by more than 6,200 publications in peer-reviewed journals (June 2009).  

"We are very glad that we can add the Hagedorn Research Institute as part of Novo Nordisk, one of the premier global pharmaceutical companies with European headquarters, to our growing list of licensees", stated Dr. E. Böhnlein, CEO of TET Systems. "This license agreement again shows that the Tet Technology provides a clear technological advantage to innovative biomedical research which translates into a strategic advantage for these pharmaceutical and biotech companies."


About TET Systems

TET Systems Holding is a privately held company located in Heidelberg, Germany. TET Systems Holding was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the Tet Technology, the most widely used method to control gene expression in higher organisms.  TET Systems Holding owns a broad patent portfolio covering the technology organized in six patent families comprising 31 granted patents and 14 patent applications.  TET Systems markets licenses to the Tet Technology through its subsidiary IP Merchandisers.  To date, more than 150 organizations have licensed the Tet Technology including academic institutions and research foundations.  The largest group of licensees are pharmaceutical and biotech companies, with 17 of the top 20 BIG Pharma (2006) being Tet Technology licensees.  

 

Contact:

TET Systems Holding GmbH & Co. KG

Dr. Ernst Böhnlein                    
Chief Executive Officer                
Phone: +49 6221 588 0400        
boehnlein@tet-systems.com

 

You can download the news here.

To top


TET Systems and Pharmasset Settle Patent Litigation

TET Systems Holding GmbH & Co. KG ("TET Systems"), a worldwide leader in controlled gene expression, today announced that TET Systems and Pharmasset, Inc. have settled patent litigation between the companies surrounding TET Systems` patented gene expression technology.  As part of the confidential settlement, the parties agreed to dismiss the litigation with prejudice and Pharmasset agreed to take a license under TET Systems` portfolio of systems for efficient, precise, and reversible control over both timing and level of gene expression in eukaryotic cells.  Under the terms of the agreement, Pharmasset will, among other things, make an undisclosed payment to TET Systems.

TET Systems was founded by Prof. Dr. H. Bujard and his colleagues.  Today, TET Systems` technology is the most widely used method to control gene expression in higher organisms.  85% of the world's leading pharmaceutical companies license the Tet technology and the broad usage of the Tet Technology is demonstrated by more than 6,200 publications in peer-reviewed journals (June 2009).  

 

About TET Systems
TET Systems Holding is a privately held company located in Heidelberg, Germany. TET Systems Holding was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the Tet Technology, the most widely used method to control gene expression in higher organisms.  TET Systems Holding owns a broad patent portfolio covering the technology organized in six patent families comprising 31 granted patents and 14 patent applications.  TET Systems markets licenses to the Tet Technology through its subsidiary IP Merchandisers.  To date, more than 150 organizations have licensed the TET Technology including academic institutions and research foundations.  The largest group of partners are pharmaceutical and biotech companies, with 17 of the top 20 BIG Pharma (2006) being TET Technology licensees.

 

You can download the PR here.

To top


Conference Update

In November (2-4), TET Systems will attend the Bio Europe 2009 conference in Vienna, Austria. We look forward to meeting all exisiting customers, Autorized Partners and new partners and interested parties who have interest in our technology or plan to establish new business models using the Tet Technology.

TET Systems attended the first EMBO Meeting in Amsterdam both as exhibitor and sponsor of a scientific symposium on Monday, August 31: "The Tet Technology and its Impact on Modern Life Sciences which we organize together with our partner Clontech." A prominent group of speakers (R.Jaenisch, D.Felsher and L.Alphey)  presented recent advances in the fields of stem cell biology, cancer disease and progression and sterile insect technology. Prof. H. Bujard, one of the inventors of the Tet Technology, provided an introductory overview.

Earlier this year, TET Systems attended the Bio 2009 in Atlanta, Georgia (May 18-21) as part of the German Pavillion.

In preparation of these conferences, we have updated our marketing material which you can download here.

We look forward to meeting you during these outstanding conference events.

To top



BioFocus DPI to apply TET Technology in high-throughput screening campaigns


Saffron Walden, UK and Heidelberg, Germany; 24 April 2009 - BioFocus DPI, a leading provider of gene-to-candidate discovery services, and TET Systems Holding, a privately-held, German-based biotech company, announced today that they have entered into an agreement to apply TET System's inducible gene technology in high-throughput screening campaigns performed for BioFocus DPI customers.

BioFocus DPI will offer TET Technology as part of its drug discovery screening service.  Through this technology, the activity of individual genes can be controlled quantitatively and reversibly in cellular assays.  This approach is particularly powerful in cases where the target is not well tolerated in the cells, since the protein will not be expressed until required for screening.

"The TET Technology allows us to build on the proven compound screening service that we offer clients.  This powerful approach will benefit discovery programs that are hindered by difficult to express targets.  Using this technology, we will be able to perform more efficient, extensive compound screening on these problematic targets," commented Dr. Kate Hilyard, VP Biological Sciences, BioFocus DPI.
 
"We are very pleased to sign this agreement with BioFocus DPI, one of the leading drug discovery service providers worldwide.  TET Technology has been used successfully for many years by most of the major pharmaceutical companies.  Through this new partnership with BioFocus DPI, a broader range of pharmaceutical and biotechnology companies will gain access to TET System`s gene expression technology," stated Dr. Ernst Boehnlein, CEO of TET Systems Holding and IP Merchandisers.


About BioFocus DPI
BioFocus DPI aims to expand its partners? drug pipelines by accelerating the gene-to-candidate discovery process.  This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry, ADME/PK services, supported by unique chemogenomic and informatics tools, and compound library acquisition, storage and distribution services.  As the service division of Galapagos, BioFocus DPI has over 250 employees in four countries worldwide.


About TET Systems Holding
TET Systems Holding is a privately held company located in Heidelberg, Germany. TET Systems Holding was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the TET Technology, the most widely used method to control gene expression in higher organisms.  TET Systems Holding owns a broad patent portfolio covering the technology organised in six patent families comprising 30 granted patents and 14 patent applications.  TET Systems markets licences to the TET Technology through its subsidiary IP Merchandisers.  To date, more than 140 organisations have licensed the TET Technology including academic institutions and research foundations.  The largest group of partners are biotech and pharmaceutical companies, with 17 of the top 20 BIG Pharma (2006) being TET Technology licensees.


All trademarks are the property of their respective owners.



CONTACTS

BioFocus DPI
Dr. Kate Hilyard
VP Biological Sciences
Tel: +44 1799 533500
kate.hilyard@glpg.com

TET Systems Holding                    
Dr. Ernst Böhnlein                    
Chief Executive Officer                
Phone: +49 6221 588 0400        
boehnlein@tet-systems.com

You can download the PR here.

To top

TET Systems signs license agreement with Stemgent

- Stemgent (www.stemgent.com) to market dox-inducible stem cell reprogramming reagents -

Heidelberg, Germany, and San Diego, CA, USA, February 11, 2009 - TET Systems Holding, a privately-held, Heidelberg-based German biotech company, Stemgent, Inc., of Cambridge, MA and San Diego, CA, USA, and Clontech Laboratories, Inc., of Mountain View, CA, USA, announced today that they have entered into a partnership enabling Stemgent to market certain research reagents for inducible stem cell technology based on the Tet Technology. Stemgent will be applying TET Systems' Tet Technology, based on essential regulatory components of the E. coli tetracycline-resistance operon, to its suite of viral vector systems for the generation of induced pluripotent stem (iPS) cells. Once established in the cell line, the inducer doxycycline, a tetracycline derivative, controls the system in a dose-dependent manner, allowing researchers to precisely modulate the expression levels of target genes such as Oct4, Sox2, and other transcription factors identified as important in generation of iPS cells.

The journal Science proclaimed reprogramming - the process by which cells are manipulated from a differentiated state to a pluripotent state, down a new pathway, or directly from one differentiated state to another - to be the Breakthrough of the Year in December 2008.

"The recent discovery that differentiated cells can be reprogrammed to become pluripotent stem cells has already provided new incentives to explore the therapeutic value of cellular therapies. This new technology enables the development of new and innovative therapies for incurable disease while avoiding the legal issues concerning the use of embryonic stem cells. Stemgent is the leading company providing reagents for this new technology to the scientific community based on their close relationship with leading stem cell scientists. We are very happy that Stemgent decided to introduce a set of inducible reagents based on the Tet Technology and welcome Stemgent to our growing family of Authorized Partners, including our primary partner, Clontech, which provides all basic research reagents for the Tet System", stated Dr. Ernst Boehnlein, CEO of TET Systems Holding and IP Merchandisers.

By licensing this technology from TET Systems, Stemgent is now able to provide more sophisticated tools to the research communities it serves, furthering its mission of advancing stem cell science.

"We are excited to enter into partnership with TET Systems," added Dr. Stephen Chang, Chief Scientific Officer of Stemgent. "Dr. Hermann Bujard's pioneering work with the Tet Technology has enabled tremendous advances in developmental biology and, now, stem cell sciences."


About TET Systems Holding - www.tet-systems.com
TET Systems Holding is a privately held company located in Heidelberg, Germany. TET Systems Holding was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the Tet Technology, the most widely used method to control gene expression in higher organisms. TET Systems Holding owns a broad patent portfolio covering the technology organised in six patent families comprising 29 granted patents and 12 patent applications. TET Systems markets licences to the Tet Technology through its subsidiary IP Merchandisers (www.IP-Merchandisers.com). To date, more than 140 organisations have licensed the Tet Technology including academic institutions and research foundations. The largest group of partners are biotech and pharmaceutical companies, with 18 of the top 20 BIG Pharma (2006) being TET Technology licensees.

About Stemgent - www.stemgent.com
Stemgent moves stem cell science forward by providing proprietary reagents and tools developed by some of the world's leading stem cell scientists.  Stemgent?s product offering has been specifically optimized for and screened against stem cells, and includes small molecules for pluripotency, self-renewal, and differentiation, as well as cytokines, antibodies, transfection reagents, and more.   Stemgent's latest innovations include viral vectors encoding transcription factors necessary for the generation of induced pluripotent stem (iPS) cells.  This unique product mix is designed to serve researchers who study stem cell biology, regenerative medicine, and those who use cells derived from stem cells as tools to advance their understanding of major diseases.  With dual headquarters in Boston, MA, and San Diego, CA, Stemgent is well positioned to serve the stem cell research market.

All trademarks are the property of their respective owners.


Contact:
TET Systems Holding     
Dr. Ernst Boehnlein     
Chief Executive Officer    
Phone: +49 (6221) 588 0400  
boehnlein@tet-systems.com


Stemgent
Sarah Neugebauer
Marketing Manager
Phone: +1 (858) 353 4482
sarah.neugebauer@stemgent.com


>>Download

To top


TET Systems signs license agreement with RIKEN BioResource Center

Heidelberg, December 3, 2008 - TET Systems Holding, a privately-held, Heidelberg-based German biotech company, and RIKEN BioResource Center (RBRC) of Koyadai Tsukuba Ibaraki, Japan, announced today that they have signed a license agreement. Under this agreement, RBRC can receive, maintain, reproduce, use and distribute laboratory animals which contain or are produced using the Tet Technology.

"We are very happy to add RIKEN BioResource Center to our growing family of partners. RBRC has an excellent reputation. With its geographic location, it is an ideal complementation of our already existing network of partnerships for the worldwide distribution of Tet transgenic animals throughout the scientific community, including academic and corporate centers", stated Dr. Ernst Boehnlein, the newly appointed CEO of TET Systems Holding and IP Merchandisers. "Elegant studies like the recent publication by H. Varmus and colleagues from Memorial Sloan Kettering, challenging the existing hypothesis regarding metastasis formation, reinforce the value of the Tet Technology for drug development, in particular the value of transgenic models to understand disease development and progression. This example further underscores the necessity to make such models available to a broad scientific community with partners like RBRC."

"We really appreciate TET Systems` licensing policy and their generous terms and conditions for not-for-profit academic users of the Tet Technology", stated Dr. Yuichi Obata, Director of RBRC.  Dr. Atsushi Yoshiki, Head of RBRC's Experimental Animal Division, added: "This license agreement allows RBRC to distribute the many useful mouse resources developed by Japanese scientists to make Tet Technology available to the scientific community for the advancement of the life sciences."

About TET Systems Holding - www.tet-systems.com
TET Systems Holding is a privately held company located in Heidelberg, Germany. TET Systems Holding was founded by Prof. Dr. H. Bujard and colleagues based on their invention of the Tet Technology, the most widely used method to control gene expression in higher organisms. TET Systems Holding owns a broad patent portfolio covering the technology organised in six patent families comprising 29 granted patents and 12 patent applications. TET Systems markets licences to the Tet Technology through its subsidiary IP Merchandisers (www.IP-Merchandisers.com). To date, more than 140 organisations have licensed the Tet Technology including academic institutions and research foundations The largest group of partners are biotech and pharmaceutical companies, with 18 of the top 20 BIG Pharma (2006) being TET Technology licensees.

About RIKEN BioResource Center - www.brc.riken.jp
RIKEN BioResource Center (RBRC), a non-profit public institution financed by the Japanese Government, is engaged in the collection, maintenance, storage, propagation, quality control and distribution of biological resources such as experimental animals, plants, cell lines, genetic materials, microbes, and associated bioinformatics in order to contribute to the international scientific community. Since 2002, RBRC has been the core facility of the National Bioresource Project (NBRP) of Japan's Ministry of Education, Culture, Sports, Science and Technology.  RBRC is a founding member of the Federation of International Mouse Resources (FIMRe) and participates in the International Mouse Strain Resource (IMSR), distributing mouse strains worldwide. 

Contact:

TET Systems Holding                   
Dr. Ernst Böhnlein                   
Chief Executive Officer               
Phone: +49 (6221) 588 0400       
boehnlein@tet-systems.com

RIKEN BioResource Center
Dr. Atsushi Yoshiki
Head of Experimental Animal Division
Phone: +81-29-836-9192


yoshiki@brc.riken.jp

 

 

>>Download

To top


15th anniversary of the Tet Technology

01/13/2008

In honor of the 15th anniversary of the Tet Technology we are pleased to present 2 articles that recently came out in Clontechniques.

In honor of the 15th anniversary of the Tet Technology we are pleased to present 2 articles recently published in ?Clontechniques?. The first article is a retrospective on key milestones in the development of the Tet Technology while the second article summarizes some of its most noteworthy applications in basic and applied research.

>> Download Flyer: 15 Years Tet Systems
>> Download Flyer: 15 Years Tet Clontech

 

To top


TET SYSTEMS HOLDING, HEIDELBERG, AND ABBOTT LABORATORIES AGREE ON TRANSFER OF RIGHTS TO PATENT PORTFOLIO OF TET TECHNOLOGY FOR GENE REGULATION

HEIDELBERG, Germany, May 2004 - TET Systems Holding GmbH announced today that Abbott Laboratories has transferred back the rights to key patents covering the control of gene expression by tetracycline-inducible gene control elements to TET Systems Holding.  The TET gene control elements allow genes to be turned on or off, either in cultured cells or in whole organisms such as yeast, plants and mammals, by exposure to the common antibiotic tetracycline.  TET Systems Holding, a company founded by the TET inventors to further develop and market the TET technology, will market the portfolio of TET Technology patents worldwide, and will provide technical support to licensees of the TET Technology to help promote successful new product development.

Under the terms of the agreement, Abbott will retain the rights to use the patents and will gain access to all TET technology improvements acquired by TET Systems Holding.  TET Systems Holding gains the rights to worldwide patents and marketing of core TET technology previously controlled by Abbott.  The transfer of patent and marketing rights from Abbott to TET Systems Holding GmbH was effective Jan. 1, 2004.


About TET Systems Holding GmbH & Co. KG
TET Systems Holding, founded in Heidelberg by Professor Hermann Bujard and the co-inventors of the TET gene control technology and of recent improved TET gene control elements, is a new company focused on marketing, supporting, and further developing TET technology.  "TET Systems Holding will serve the needs of licensees to successfully apply the existing TET Technology, and to adapt recent improved TET inventions for both current and future applications," said Prof. Bujard, President of TET Holding GmbH & Co. KG.  "We are strongly committed to further developing TET technology in order to maintain its position as the leading gene regulation technology for life science research and development, commercial and production applications."

Updated information on TET Systems Holding, will be available soon at www.tet-systems.com

Contact:
Hans Peter Kneubuehl
TET Systems Holding GmbH & Co. KG
Tel +49 6221 588 04 00
eMail:  kneubuehl@tet-systems.de

To top